Business · 28/05/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for MYRBETRIQ Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially set a regulatory review period for the patent extension of MYRBETRIQ, a human drug product, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →